开发裂谷热疫苗的新方法。
Novel approaches to develop Rift Valley fever vaccines.
机构信息
Department of Pathology, The University of Texas Medical Branch Galveston, TX, USA.
出版信息
Front Cell Infect Microbiol. 2012 Oct 26;2:131. doi: 10.3389/fcimb.2012.00131. eCollection 2012.
Abstract
Rift Valley fever (RVF) is endemic to sub-Saharan Africa, and has spread into Madagascar, Egypt, Saudi Arabia, and Yemen. Rift Valley fever virus (RVFV) of the family Bunyaviridae, genus Phlebovirus causes hemorrhagic fever, neurological disorders or blindness in humans, and high rate abortion and fetal malformation in ruminants. RVFV is classified as a Category A Priority pathogen and overlap select agent by CDC/USDA due to its potential impact on public health and agriculture. There is a gap in the safety and immunogenicity in traditional RVF vaccines; the formalin-inactivated RVFV vaccine TSI-GSD-200 requires three doses for protection, and the live-attenuated Smithburn vaccine has a risk to cause abortion and fetal malformation in pregnant ruminants. In this review, problems of traditional vaccines and the safety and efficacy of recently reported novel RVF candidate vaccines including subunit vaccines, virus vector, and replicons are discussed.
摘要
裂谷热（RVF）是撒哈拉以南非洲的地方病，已蔓延至马达加斯加、埃及、沙特阿拉伯和也门。布尼亚病毒科、白蛉病毒属的裂谷热病毒（RVFV）可引起人类出血热、神经紊乱或失明，并导致反刍动物流产率高和胎儿畸形。由于裂谷热病毒对公共卫生和农业的潜在影响，美国疾病控制与预防中心（CDC）/美国农业部（USDA）将其列为 A 类优先病原体和选择剂。传统 RVF 疫苗在安全性和免疫原性方面存在不足；福尔马林灭活的 RVFV 疫苗 TSI-GSD-200 需接种三剂才能提供保护，而减毒活疫苗 Smithburn 有导致妊娠反刍动物流产和胎儿畸形的风险。在这篇综述中，讨论了传统疫苗存在的问题，以及最近报道的新型 RVF 候选疫苗（包括亚单位疫苗、病毒载体和复制子）的安全性和有效性。
相似文献
1
Novel approaches to develop Rift Valley fever vaccines.开发裂谷热疫苗的新方法。
Front Cell Infect Microbiol. 2012 Oct 26;2:131. doi: 10.3389/fcimb.2012.00131. eCollection 2012.
2
Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.单周期可复制的裂谷热病毒突变体作为安全的候选疫苗
Virus Res. 2016 May 2;216:55-65. doi: 10.1016/j.virusres.2015.05.012. Epub 2015 May 27.
3
Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.裂谷热疫苗：减毒活疫苗候选株MP-12的安全性与有效性概述
Expert Rev Vaccines. 2017 Jun;16(6):601-611. doi: 10.1080/14760584.2017.1321482. Epub 2017 May 2.
4
Candidate vaccines for human Rift Valley fever.人类裂谷热候选疫苗。
Expert Opin Biol Ther. 2019 Dec;19(12):1333-1342. doi: 10.1080/14712598.2019.1662784. Epub 2019 Sep 6.
5
Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep.缺失 NSm 的重组裂谷热病毒 MP-12 作为候选疫苗在绵羊中的效力。
Vaccine. 2014 Apr 25;32(20):2345-9. doi: 10.1016/j.vaccine.2013.12.064. Epub 2014 Jan 24.
6
Rift valley fever vaccines.裂谷热疫苗。
Vaccine. 2009 Nov 5;27 Suppl 4:D69-72. doi: 10.1016/j.vaccine.2009.07.046.
7
Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.裂谷热病毒MP-12疫苗通过S、M和L基因片段的部分减毒组合而完全减毒。
J Virol. 2015 Jul;89(14):7262-76. doi: 10.1128/JVI.00135-15. Epub 2015 May 6.
8
Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice.裂谷热病毒 MP-12 疫苗编码的托斯卡纳病毒 NSs 在小鼠中保留神经侵袭性。
J Gen Virol. 2013 Jul;94(Pt 7):1441-1450. doi: 10.1099/vir.0.051250-0. Epub 2013 Mar 20.
9
Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12ΔNSm21/384 vaccine candidate for sheep, goats and calves.绵羊、山羊和小牛用减毒活 Rift Valley 热重组 arMP-12ΔNSm21/384 疫苗候选物的安全性和免疫原性。
Vaccine. 2019 Mar 14;37(12):1642-1650. doi: 10.1016/j.vaccine.2019.01.067. Epub 2019 Feb 14.
10
Safety and immunogenicity of inactivated Rift Valley Fever Smithburn viral vaccine in sheep.绵羊接种裂谷热史密斯伯恩病毒灭活疫苗的安全性和免疫原性。
Virol J. 2023 Oct 3;20(1):221. doi: 10.1186/s12985-023-02180-2.
引用本文的文献
1
Rift Valley Fever Phlebovirus Reassortment Study in Sheep.裂谷热嗜肝病毒在绵羊中的重配研究。
Viruses. 2024 May 30;16(6):880. doi: 10.3390/v16060880.
2
RT-qPCR genotyping assays for differentiating Rift Valley fever phlebovirus strains.用于区分裂谷热病毒株的 RT-qPCR 基因分型检测。
J Virol Methods. 2023 May;315:114693. doi: 10.1016/j.jviromet.2023.114693. Epub 2023 Feb 16.
3
A Qualitative Study on Gendered Barriers to Livestock Vaccine Uptake in Kenya and Uganda and Their Implications on Rift Valley Fever Control.关于肯尼亚和乌干达牲畜疫苗接种中性别障碍及其对裂谷热防控影响的定性研究。
Vaccines (Basel). 2019 Aug 8;7(3):86. doi: 10.3390/vaccines7030086.
4
Transcriptome profiling in Rift Valley fever virus infected cells reveals modified transcriptional and alternative splicing programs.转录组谱分析显示裂谷热病毒感染细胞中修改的转录和可变剪接程序。
PLoS One. 2019 May 28;14(5):e0217497. doi: 10.1371/journal.pone.0217497. eCollection 2019.
5
Emerging viruses and current strategies for vaccine intervention.新兴病毒与疫苗干预的现行策略。
Clin Exp Immunol. 2019 May;196(2):157-166. doi: 10.1111/cei.13295.
6
RVFV Infection in Goats by Different Routes of Inoculation.不同接种途径感染山羊 RVFV。
Viruses. 2018 Dec 12;10(12):709. doi: 10.3390/v10120709.
7
Molecular aspects of Rift Valley fever virus and the emergence of reassortants.裂谷热病毒的分子特征及重配病毒的出现
Virus Genes. 2019 Feb;55(1):1-11. doi: 10.1007/s11262-018-1611-y. Epub 2018 Nov 13.
8
Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model.在小鼠模型中不同遗传谱系的裂谷热静脉病毒株的不同毒力
PLoS One. 2017 Dec 21;12(12):e0189250. doi: 10.1371/journal.pone.0189250. eCollection 2017.
9
Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.裂谷热病毒感染抗病毒治疗药物研发的最新进展。
Future Virol. 2017 Nov;12(11):651-665. doi: 10.2217/fvl-2017-0060. Epub 2017 Oct 23.
10
Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain.裂谷热病毒 rMP12-GM50 株的衰减和保护效力。
Vaccine. 2017 Dec 4;35(48 Pt B):6634-6642. doi: 10.1016/j.vaccine.2017.10.036. Epub 2017 Oct 20.
本文引用的文献
1
Molecular biology and genetic diversity of Rift Valley fever virus.裂谷热病毒的分子生物学与遗传多样性。
Antiviral Res. 2012 Sep;95(3):293-310. doi: 10.1016/j.antiviral.2012.06.001. Epub 2012 Jun 16.
2
The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine.双链 RNA 依赖性蛋白激酶 PKR 的显性负抑制作用提高裂谷热病毒 MP-12 疫苗的效力。
J Virol. 2012 Jul;86(14):7650-61. doi: 10.1128/JVI.00778-12. Epub 2012 May 9.
3
MBT/Pas mouse: a relevant model for the evaluation of Rift Valley fever vaccines.MBT/Pas 小鼠：裂谷热疫苗评价的相关模型。
J Gen Virol. 2012 Jul;93(Pt 7):1456-1464. doi: 10.1099/vir.0.042754-0. Epub 2012 Apr 18.
4
Efficacy of three candidate Rift Valley fever vaccines in sheep.三种里夫特山谷热候选疫苗在绵羊中的效力。
Vaccine. 2012 May 14;30(23):3423-9. doi: 10.1016/j.vaccine.2012.03.027. Epub 2012 Mar 24.
5
Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge.单次免疫病毒复制子颗粒可快速、有效地预防裂谷热病毒感染。
J Virol. 2012 Apr;86(8):4204-12. doi: 10.1128/JVI.07104-11. Epub 2012 Feb 15.
6
Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep.裂谷热病毒疫苗缺失 NSs 和 NSm 基因，对成年和怀孕绵羊具有安全性、非致畸性，可预防病毒血症、发热和流产。
J Virol. 2011 Dec;85(24):12901-9. doi: 10.1128/JVI.06046-11. Epub 2011 Oct 5.
7
Creation of a nonspreading Rift Valley fever virus.裂谷热病毒非扩散株的构建。
J Virol. 2011 Dec;85(23):12622-30. doi: 10.1128/JVI.00841-11. Epub 2011 Sep 28.
8
Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice.重组裂谷热疫苗可在狒狒中诱导产生保护性抗体水平，并在小鼠中抵抗致死性挑战。
Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14926-31. doi: 10.1073/pnas.1112149108. Epub 2011 Aug 23.
9
Creation of a recombinant Rift Valley fever virus with a two-segmented genome.创建具有两段基因组的重组裂谷热病毒。
J Virol. 2011 Oct;85(19):10310-8. doi: 10.1128/JVI.05252-11. Epub 2011 Jul 27.
10
The pathogenesis of Rift Valley fever.裂谷热的发病机制。
Viruses. 2011 May;3(5):493-519. doi: 10.3390/v3050493.
Zotero 插件